Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE
· Real-Time Price · USD
9.77
0.86 (9.65%)
At close: Aug 15, 2025, 3:59 PM
9.65% (1D)
| Bid | 9.8 |
| Market Cap | 1.55B |
| Revenue (ttm) | 93.95M |
| Net Income (ttm) | -129.87M |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -12.21 |
| Forward PE | -6.86 |
| Analyst | Buy |
| Ask | 9.87 |
| Volume | 2,551,687 |
| Avg. Volume (20D) | 1,357,866 |
| Open | 8.98 |
| Previous Close | 8.91 |
| Day's Range | 8.96 - 9.79 |
| 52-Week Range | 5.04 - 16.74 |
| Beta | -0.96 |
Analyst Forecast
According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Wave Life Sciences Ltd. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+1.39%
Wave Life Sciences shares are trading higher after...
Unlock content with
Pro Subscription
3 months ago
-17.08%
Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.
2 weeks ago · fool.com
Wave (WVE) Q2 Revenue Drops 56%Wave (WVE) Q2 Revenue Drops 56%
1 month ago · seekingalpha.com
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 MonthsWave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying oppor...